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Abstract: AIMS Heart failure oral therapies (HFOTs), including beta-blockers (BB), renin-angiotensin
system inhibitors (RASi) and mineralocorticoid receptor antagonists, administered before hospital dis-
charge after acute heart failure (AHF) might improve outcome. However, concerns have been raised
because early administration of HFOTs may worsen patient’s condition. We hypothesized that HFOTs at
hospital discharge might be associated with better post-discharge survival. METHODS AND RESULTS
The study population was composed of 19 980 AHF patients from the GREAT registry. The primary and
secondary outcomes were 90-day and 1-year all-cause mortality, respectively. Survival was estimated with
univariate and covariate-adjusted Cox proportional hazards regression models for the whole population
and after propensity-score matching. HFOTs at discharge were consistently associated with no excess
mortality in the unadjusted and adjusted analyses of the whole and matched cohorts. In the matched
cohort, BB and RASi at discharge were associated with lower 90-day mortality risks compared to the
respective untreated groups [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.46-0.69; and HR 0.53,
95% CI 0.42-0.66, respectively]. The favourable associations of BB and RASi at discharge with 90-day
mortality were present in many subgroups including patients with reduced or preserved left ventricular
ejection fraction and persisted up to 1 year after discharge. The combination of RASi and BB was as-
sociated with an even lower risk of death than RASi or BB alone. CONCLUSIONS Administration of
HFOTs at hospital discharge is associated with better survival of AHF patients.
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Aims Heart failure oral therapies (HFOTs), including beta-blockers (BB), renin–angiotensin system inhibitors (RASi) and
mineralocorticoid receptor antagonists, administered before hospital discharge after acute heart failure (AHF) might
improve outcome. However, concerns have been raised because early administration of HFOTs may worsen patient’s
condition. We hypothesized that HFOTs at hospital discharge might be associated with better post-discharge survival.
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Methods
and results
The study population was composed of 19 980 AHF patients from the GREAT registry. The primary and secondary
outcomes were 90-day and 1-year all-cause mortality, respectively. Survival was estimated with univariate and
covariate-adjusted Cox proportional hazards regression models for the whole population and after propensity-score
matching. HFOTs at discharge were consistently associated with no excess mortality in the unadjusted and adjusted
analyses of the whole and matched cohorts. In the matched cohort, BB and RASi at discharge were associated with
lower 90-day mortality risks compared to the respective untreated groups [hazard ratio (HR) 0.56, 95% confidence
interval (CI) 0.46–0.69; and HR 0.53, 95% CI 0.42–0.66, respectively]. The favourable associations of BB and RASi
at discharge with 90-day mortality were present in many subgroups including patients with reduced or preserved
left ventricular ejection fraction and persisted up to 1 year after discharge. The combination of RASi and BB was
associated with an even lower risk of death than RASi or BB alone.
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Conclusions Administration of HFOTs at hospital discharge is associated with better survival of AHF patients.
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Introduction
Acute heart failure (AHF) is a common and potentially fatal condi-
tion. The prognosis of AHF is poor, with a 5–8% rate of in-hospital
mortality and 10% additional post-discharge mortality.1–3 This
immediate post-discharge period of risk usually lasts up to 90 days
and is known as the ‘vulnerable phase’.4
The pathophysiology of the vulnerable phase remains controver-
sial. Some suggested a post-discharge increase in left ventricular
filling pressure while other studies suggested underutilization of
heart failure oral therapies (HFOTs) at discharge.4 HFOTs, includ-
ing beta-blockers (BB), renin–angiotensin system inhibitors (RASi:
angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers) and mineralocorticoid receptor antagonists (MRA) have
long been shown to markedly improve outcomes in stable heart
failure (HF) with reduced left ventricular ejection fraction (HFrEF).
Most recent European and North American HF guidelines recom-
mend the maintenance and/or introduction of HFOT at hospital
discharge in HFrEF, based on a few studies showing that BB with-
drawal in AHF patients was associated with an increased risk of
post-discharge death.5–8 However, the maintenance or early intro-
duction of HFOTs in patients who are fragile, still suffering or just
recovered from the AHF crisis is sub-optimal, especially in old
patients.9,10 Data on the effect of the maintenance, introduction,
and withdrawal of RASi and/or MRA, alone or combined with BB,
during AHF hospitalization are therefore needed.
Moreover, since many AHF patients present with preserved
left ventricular ejection fraction (HFpEF), no data exist whether
HFOTs are beneficial in those patients. Despite demographic and
clinical differences, the outcomes following AHF hospitalization in
HFpEF patients are as poor as those in patients with HFrEF.11 Due
to negative trials,12–15 recent European and North American HF
guidelines recommended not administering oral medications either
in chronic or, by extension, decompensated HFpEF patients.5,8
In the present study, we hypothesize that HFOTs at hospital
discharge, whether alone or combined, might be associated with
better outcomes (i) during the ‘post-discharge vulnerable phase’,
and (ii) in all AHF patients, including those with HFpEF. Finally, as
the maintenance, introduction and withdrawal of HFOT may be
influenced by the severity of HF and/or of co-morbidities, their




The study population was derived from the GREAT registry, an inter-
national, multicentre, prospective observational cohort of 25 971
adult patients with AHF as the main diagnosis at hospital admission.
Details on the constitution of the GREAT registry have been previously
described in detail.16,17 Acute HF includes both de novo HF and acutely
decompensated HF as defined by the European Society of Cardiol-
ogy (ESC) and American College of Cardiology Foundation/American
Heart Association (ACCF/AHA) guidelines.5,7 The exclusion criteria
for this study were mortality during index hospitalization, unknown



















































































.. on BB or RASi at discharge. To limit the heterogeneity of the results,
patients included in small centres were also excluded from the study.
Following the inclusion and exclusion criteria, the study population
comprised 19 980 AHF patients discharged alive from hospitals in 10
countries and two continents (France, Switzerland, Italy, Spain, Finland,
Czech Republic, Saudi Arabia, China, Korea, Japan) for whom both
medication at discharge and 1-year outcome were available (Figure 1).
Study outcomes
The primary outcome of the study was defined as 90-day all-cause mor-
tality according to the prescribed HF therapies at hospital discharge.
Three different classes of medication (BB, RASi and MRA) were consid-
ered. The secondary outcome was 1-year all-cause mortality according
to the prescribed HF therapies at hospital discharge.
Statistical analysis
Survival was plotted with a Kaplan–Meier curve, and Cox proportional
hazards regression models (univariate, covariate-adjusted and strat-
ified for matched pairs after propensity-score matching) were used
to estimate the associations between treatment regimen at discharge
and the study outcomes. Given the observational nature of the data,
treatment allocation was not randomly assigned in the study popula-
tion and therefore we used propensity-score matching to reduce the
risk of bias due to confounders, and the causal effects of the vari-
ous treatment regimens on the outcomes could be more precisely
estimated.18 Each patient treated with a regimen was matched to one
untreated control with a similar propensity score. Variables included
in the propensity score model were selected from the available base-
line variables based on known associations between treatment reg-
imens and/or study outcomes: demographic characteristics [gender,
age, body mass index, geographic region (Europe, Asia), medical his-
tory (arterial hypertension, diabetes mellitus, ischaemic heart disease,
chronic HF, left ventricular ejection fraction (LVEF) >40%, atrial fibril-
lation, chronic obstructive pulmonary disease (COPD)], treatment at
admission (BB, RASi, MRA, diuretics, vasodilators, aspirin, statin), bio-
logical indicators at admission [haemoglobin, sodium <136 mmol/L,
estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2], and
haemodynamics at admission (systolic and diastolic blood pressure,
heart rate). Treated and not treated patients were matched accord-
ing to the nearest neighbor approach within a caliper width of 0.01. To
assess the balance of covariates between the two groups before and
after propensity-score matching, mean standardized differences (MSD)
were used. A MSD <10% was considered to support the assump-
tion of balance between groups. Subgroup analyses were performed
in pre-specified subgroups according to age, sex, geographic region,
LVEF, systolic blood pressure, heart rate, B-type natriuretic peptide
(BNP), eGFR, sodium, history of HF, history of atrial fibrillation, his-
tory of COPD, type and cause of AHF, length of hospital stay, and prior
treatment before hospital admission. The results are expressed as the
median (interquartile range) or count (percentage) as appropriate. The
risk of death of patients treated with a drug class, or a combination
thereof (‘treated’) compared to patients not receiving the same drug
class or combination (‘untreated’) is expressed as hazard ratio (HR)
and 95% confidence interval (CI). A P-value of <0.05 was considered
statistically significant. All statistical analyses were performed using
R statistical software (The ‘R’ Foundation for Statistical Computing,
Vienna, Austria) with the statistical package MatchIt for the matching
process.
© 2017 The Authors
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Figure 1 Flowchart of the study population. The study population consisted of a cohort of 19 980 acute heart failure (AHF) patients
discharged alive for whom beta-blockers (BB) and renin–angiotensin system inhibitors (RASi) at discharge and 1-year outcome data were
available. †Information about mineralocorticoid receptor antagonists (MRA) at discharge was lacking for 2991 included patients.
Results
Study population
The study population consisted of 19 980 AHF patients, predomi-
nantly men, with a median age of 72 (62–80) years and a high preva-
lence of cardiovascular risk factors. A substantial proportion (37%)
of AHF patients had preserved ejection fraction (LVEF >40%), and
ischaemic cardiomyopathy accounted for nearly half of all HF eti-
ologies. The median BNP level at admission was 768 (383–1452)
pg/mL. The baseline characteristics of the entire study population
are summarized in Table 1. The median length of hospital stay was
10 (6–18) days. During the follow-up, the mortality rates at 90
days and 1 year were 7% and 16%, respectively.
At discharge, BB were prescribed to 12 975 patients (65%), RASi
to 14 314 patients (72%), and a combination of BB and RASi to 10
443 patients (52%), whereas 3134 patients (16%) were treated with
neither BB nor RASi (Table 2 and Supplementary material online,
Table S1). Mineralocorticoid receptor antagonists were prescribed
to 7672 patients (45%). The baseline characteristics of patients
according to their HF therapies at discharge are reported in the
Supplementary material online, Table S2.
Effect of heart failure oral therapies
at discharge on acute heart failure
outcomes
The unadjusted and adjusted analyses of the whole and matched










































.. associated with no excess mortality at 90 days (Figures 2–4 and
Supplementary material online, Tables S3 and S4).
Patients receiving BB at discharge had a lower 90-day mortality
compared to BB-untreated patients (HR 0.72, 95% CI 0.65–0.80).
Similarly, patients on RASi at discharge had a lower 90-day mortality
than RASi-untreated patients (HR 0.52, 95% CI 0.47–0.58). Similar
beneficial associations between BB and RASi at discharge and
90-day mortality were observed after covariate adjustments were
performed (Figure 2A and Supplementary material online, Table
S3). Conversely, no difference in 90-day mortality was found
between patients treated or untreated with MRA (HR 1.00, 95%
CI 0.89–1.12).
After propensity-score matching, the MSD of all covariates were
reduced to below 10%, indicating an adequate covariate balance
between BB-, RASi- and MRA-treated patients and their respective
untreated patients (Supplementary material online, Table S4 and
Figure S1). In the matched cohorts, patients on BB at discharge
(n=2819) had a lower 90-day mortality than BB-untreated patients
(HR 0.56, 95% CI 0.46–0.69). A similar lower mortality was
observed in patients on RASi at discharge (n=1919) compared to
matched RASi-untreated patients (HR 0.53, 95% CI 0.42–0.66). In
contrast, no difference in 90-day mortality was found in patients
treated with MRA (n=3391) compared to matched MRA-untreated
patients (HR 1.00, 95% CI 0.83–1.21).
Figure 2 illustrates the persistence of the favourable associations
of BB and RASi at discharge with mortality beyond the first 90
days after discharge. Indeed, patients on BB (HR 0.62, 95% CI
0.55–0.71) and RASi (HR 0.62, 95% CI 0.53–0.72) at discharge
had a lower 1-year mortality than matched patients who were not
© 2017 The Authors
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Table 1 Baseline characteristics of the study
population (n=19 980)
Medical history
Female gender 8442 (42%)
Age, years 72 (62–80)
Body mass index, kg/m2 25 (22–29)
Arterial hypertension 13 176 (66%)
Diabetes mellitus 8474 (43%)
Ischaemic cardiomyopathy 8695 (44%)
Chronic heart failure 8667 (44%)
LVEF >40% 6344 (37%)
Atrial fibrillation 5854 (31%)
BB at admission 8136 (41%)
RASi at admission 12 482 (63%)
MRA at admission 7961 (47%)
Diuretic at admission 9052 (56%)
Haemodynamics at admission
Systolic blood pressure, mmHg 135 (115–159)
Diastolic blood pressure, mmHg 80 (67–90)
Heart rate, b.p.m. 89 (74–108)
Biology at admission
Haemoglobin, g/L 137 (115–112)
Sodium >136 mmol/L 13 709 (70%)
Potassium, mmol/L 4.1 (3.9–4.6)
eGFR <60 mL/min/1.73 m2 8213 (41%)
BNP, pg/mL 768 (383–1452)
BB, beta-blocker; BNP, B-type natriuretic peptide; eGFR, estimated glomeru-
lar filtration rate; LVEF, left ventricular ejection fraction; MRA, miner-
alocorticoid receptor antagonist; RASi, renin–angiotensin system inhibitor
(angiotensin-converting enzyme inhibitor or angiotensin receptor blocker).
treated with BB or RASi (HR 0.62, 95% CI 0.55–0.71; and HR
0.62, 95% CI 0.53–0.72, respectively). Conversely, no favourable
association with 1-year mortality was found in patients treated
with MRA compared to MRA-untreated patients (HR 0.97, 95%
CI 0.86–1.10).
Effect of heart failure oral therapies
at discharge on outcomes in various
subgroups
Heart failure oral therapies at discharge, compared to matched
untreated patients, showed no excess 90-day mortality in high
risk AHF patients, including those with low natraemia, high BNP,
advanced HF, impaired kidney function and a history of COPD.
Similarly, no excess in 90-day mortality was observed when HFOTs
were given at hospital discharge in patients whose length of stay
was shorter than 7 days.
Figure 3 and Supplementary Table S5 show a consistent associa-
tion between receiving BB or RASi at discharge and reduced 90-day
mortality in almost all study subgroups. Notably, favourable asso-
ciations of BB and RASi at discharge with 90-day mortality were
present in both classes of LVEF: HFrEF (HR 0.57, 95% CI 0.44–0.73;
and HR 0.47, 95% CI 0.36–0.61, respectively) and HFpEF (HR 0.56,



















































































.. and in patients in whom HFOT was maintained (HFOT at
admission) or introduced (no HFOT on admission). Though
favourable, the associations between BB and RASi at discharge
and short-term mortality were not statistically significant in AHF
patients with low plasma BNP levels at admission or those with
ischaemia or a history of COPD. In patients with impaired renal
function, RASi at discharge also showed no association with
short-term mortality.
Patients treated with MRA at discharge, compared to matched
patients untreated with MRA, showed no excess in 90-day mortal-
ity in all study subgroups except a non-significant increased risk of
death in patients with atrial fibrillation. Interestingly, the subgroup
of patients with HFpEF, but not HFrEF, showed a positive associ-
ation between oral MRA at discharge and 90-day mortality (HR
0.70, 95% CI 0.49–0.99).
Combination of heart failure oral
therapies at discharge and outcome
in acute heart failure
Because receiving BB or RASi at discharge, but not MRA, had
marked favourable associations with the outcome, we tested the
association of the combination of BB and RASi with post-discharge
outcomes. Figure 4A and B show an additionally lower 90-day
mortality of patients treated with a combination of RASi and BB
(n=1178) compared to matched patients treated with BB alone
(HR 0.47, 95% CI 0.34–0.64). Figure 4A and C further show
the benefits on 90-day mortality of the combination of BB and
RASi (n=1876) compared to matched patients treated with RASi
alone (HR 0.75, 95% CI 0.57–0.99). The favourable association of
combined BB and RASi with the reduced risk of death remained
substantial up to 1 year after the acute episode: patients treated
with RASi on top of BB and patients treated with BB on top of RASi
had a lower 1-year mortality than their respective matched patients
treated with BB or RASi alone (HR 0.64, 95% CI 0.52–0.79; and
HR 0.72, 95% CI 0.60–0.85, respectively).
Figure 4D further shows the striking difference in 1-year mor-
tality between patients receiving dual therapy (BB and RASi), BB
or RASi alone and those not treated with either BB or RASi at
discharge in the entire AHF cohort. Patients with AHF receiving
neither BB nor RASi at discharge had a striking excess in 90-day
mortality (10.6%) compared to patients on full HFOT at discharge
(3.2%) (Figure 4D).
Discussion
The global pandemic of HF represents a medical and financial pri-
ority in the modern healthcare system. However, while standard
management is articulated in clinical practice guidelines, surpris-
ingly few data exist regarding the optimal application of drug ther-
apies, treatment goals are frequently not met, and standards for
treating HFpEF (accounting for up to half of global HF cases) are
not established. One of the obstacles limiting the early prescription
of HFOTs at discharge from HF hospitalization might be related
to the adverse effects of these drugs while patients are still fragile.
© 2017 The Authors
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Demographics
Female gender 4044 (39%) 1063 (42%) 1903 (49%) 1431 (46%) <0.001
Age, years 70.3 (60–79) 71.9 (61–80) 76 (66–83) 72.8 (61–81) <0.001
Body mass index, kg/m2 26.1 (23–30) 25.1 (22–29) 24.3 (22–28) 23.8 (21–27) <0.001
Medical history
Arterial hypertension 7252 (70%) 1569 (62%) 2642 (69%) 1713 (55%) <0.001
Diabetes mellitus 4466 (43%) 1049 (42%) 1442 (37%) 987 (32%) <0.001
Ischaemic heart disease 5124 (49%) 1136 (45%) 1360 (36%) 1215 (39%) <0.001
Chronic heart failure 4692 (46%) 1184 (47%) 1609 (43%) 1182 (38%) <0.001
LVEF >40% 2940 (31%) 884 (38%) 1337 (46%) 1127 (48%) <0.001
Atrial fibrillation 2842 (28%) 810 (33%) 1300 (35%) 902 (29%) <0.001
Treatment at admission
BB 5457 (53%) 1482 (59%) 582 (15%) 488 (19%) <0.001
RASi 7879 (75%) 358 (14%) 3208 (83%) 745 (24%) <0.001
MRA 2574 (28%) 606 (28%) 823 (25%) 497 (18%) <0.001
Diuretic 5062 (54%) 1289 (57%) 1664 (57%) 1037 (58%) 0.002
Biology at admission
Hemoglobin, g/L 13 (11.4–14.4) 12.3 (10.6–13.9) 12.3 (10.8–13.8) 12.4 (10.7–13.9) <0.001
Sodium >136 mmol/L 7207 (71%) 1686 (67%) 2699 (72%) 2044 (68%) <0.001
eGFR <60 mL/min/1.73 m2 4476 (43%) 847 (34%) 1533 (40%) 1270 (42%) <0.001
BNP, pg/mL 826 (428–1500) 772 (388–1460) 661 (307–1261) 700 (332–1499) <0.001
Haemodynamics at admission
Systolic blood pressure, mmHg 138 (117–160) 130 (110–150) 140 (120–160) 127 (110–147) <0.001
Diastolic blood pressure, mmHg 80 (70–93) 76 (65–88) 80 (68–90) 73 (62–84) <0.001
Heart rate, b.p.m. 90 (75–110) 89 (74–109) 88 (72–107) 85 (72–103) <0.001
BB, beta-blocker; BNP, B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor
antagonist; RASi, renin–angiotensin system inhibitor (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker).
Accordingly, we sought to examine potential benefits of pharmaco-
logical treatments indicated in HFrEF on post-discharge outcomes
using a large, intercontinental AHF registry.
In this study, we found that treatment with oral BB, RASi and
MRA should be maintained or introduced before hospital discharge
in AHF patients. Maintenance or introduction of HFOT may be
challenging in AHF, as patients are admitted with dyspnoea and
other signs and symptoms including altered heart rate and/or
blood pressure and often deteriorated kidney and/or liver function.
When AHF patients survive and recover from this acute phase and
become stable, the introduction of HFOT may still be challenging,
as the time available to optimize HF therapy may be short due to
financial penalties incurred when a hospital stay exceeds a certain
number of days. Hence, physicians may hesitate to introduce HFOT
before hospital discharge. The present study shows that all HFOTs
should be introduced early in all study subgroups, including those
with a high risk of poor outcomes, ideally before discharge, or in
case of persistent instability as soon as possible during the following
outpatient visits.
Our study showed that 90-day mortality of AHF patients
was three times greater in patients who did not receive HFOT
at discharge compared to those with full HFOT. While rapid
and beneficial effects of oral BB on mortality in chronic HF are



































.. hospitalization for AHF. Limited data suggest that the continuation
or administration of BB during the index hospitalization is associ-
ated with improved short-term survival.19,20 Furthermore, a very
recent meta-analysis by Prins and colleagues showed detrimental
effects of BB discontinuation on short-term mortality in patients
admitted with AHF.21 The present study, by reducing allocation
bias through propensity-score matching, did not find any signal of
harm and conversely shows 40% lower rates in both short-term
and 1-year mortality in patients treated with oral BB before
hospital discharge compared to patients untreated with oral BB
at discharge. Similarly, our study also shows a 40% lower risk of
both short- and long-term post-discharge risk of death associated
with the use of oral RASi in AHF. Fonarow and coworkers pre-
viously reported a trend toward reduced short-term mortality
associated with oral RASi treatment at hospital discharge; how-
ever, the process–outcome link lost significance after propensity
adjustment.22 Perhaps more notably, we found that combined
therapy with BB and RASi was associated with a lower mortality
than BB or RASi alone, with an additional 25–50% lower risk
of short- and long-term mortality. In summary, patients who are
not receiving HFOT at discharge are strikingly ‘vulnerable’ in the
post-discharge phase.
Our study showed that oral MRA at discharge was neither asso-
ciated with excess mortality nor with a favourable association with
© 2017 The Authors
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p < 0.0001 p = 0.34
Figure 2 Survival according to treatment at discharge in the matched cohort. Panel A shows the hazard ratios (HR) and 95% confidence
intervals (CI) of the unadjusted, adjusted and propensity score (PS)-matched models for 90-day and 1-year mortality according to treatment
at discharge. Panels B–D illustrate the survival of treated patients (continuous line) and PS-matched untreated patients (dotted line) for
beta-blockers (BB) (A, n=5638), renin–angiotensin system inhibitors (RASi: angiotensin-converting enzyme inhibitor or angiotensin receptor
blocker) (B, n=3838), and mineralocorticoid receptor antagonists (MRA) (C, n=6782).
post-discharge outcome, except for the subgroup of AHF with pre-
served LVEF. The lack of favourable association between oral MRA
at discharge and outcome contrasts with the beneficial associations
seen with oral BB and/or RASi at discharge and with previous trials
showing marked reductions in long-term mortality associated with
MRA treatment in stable chronic HFrEF patients.23–25 However,
our results are derived from a ‘real-world’ cohort, a completely
different setting from that of trials, and are in line with other recent
‘real-world’ studies reporting modest (if any) effects of spironolac-
tone on mortality in HF, especially in mild forms.26–29 A possible
explanation for the lack of benefit of MRA might be related to the
occurrence of severe hyperkalaemia in MRA-treated patients.26–29



















.. been related to a higher incidence of drug discontinuation due to
hyperkalaemia. The potential availability of new potassium-lowering
agents could increase MRA persistence and then result in a more
favourable outcome. We acknowledge that our registry did not
distinguish between the two recommended MRA (spironolactone
or eplerenone); however, we assume that the vast majority of
MRA-treated patients in our study received spironolactone. Our
results do not in any way refute the benefits of MRA therapy in
patients with stabilized chronic HF; rather, they suggest that in the
early days following AHF, its benefit is less clear. More data regard-
ing the use of MRA in AHF are needed.
The subgroup analysis further showed favourable associations
between oral BB and RASi at discharge and short-term outcomes
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Figure 3 Subgroup analyses for 90-day mortality. AHF, acute heart failure; BB, beta-blockers; CI, confidence interval; COPD, chronic obstruc-
tive pulmonary disease; HFOT, heart failure oral therapy; HR, hazard ratio; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid
receptor antagonists; RASi, renin–angiotensin system inhibitors (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker).
ADHF, acute decompensated heart failure.
in almost all study subgroups, including those with a short hospital
length of stay, patients from Europe or Asia, and surprisingly in
patients with both reduced or preserved LVEF. The subgroup anal-
ysis further showed a unique favourable association between oral
MRA at discharge and short-term outcomes in AHFwith preserved
LVEF (defined as LVEF ≥40%, which includes also the ‘mid-range’
group according to the most recent ESC guidelines). This is clearly
intriguing, as all HF therapies have been shown to reduce long-term
mortality of chronic stable HFrEF, but not HFpEF, patients. One
might speculate that the pathophysiological imbalances during the
vulnerable post-discharge phase, including neurohumoral activa-
tion and myocardial ischaemia, may, at least in part, be reduced
by treatment with BB and RASi through similar mechanisms in
HFrEF and HFpEF patients.4 Heart failure oral therapy might also
improve some co-morbidities in HFpEF patients. Accordingly, our
data favour the use of full HFOT at discharge in all AHF patients.
Heart failure incidence and prevalence are rising, in part


























. non-cardiovascular illnesses and argues for a global effort toward
the improved diagnosis and management of HF.30 Unfortunately,
it remains quite clear that the ability of healthcare providers and
patients alike to recognize the symptoms/signs of HF and to ensure
quality care is limited. There is not a more important time to estab-
lish quality care than in the period following hospitalization for AHF,
as this represents a ‘vulnerable period’ associated with a substan-
tial risk of downward decline, readmission, and death. Optimizing
how patients are managed at this pivotal moment is clearly a prior-
ity: with global rates of the incidence and prevalence of HF on the
rise, the associated morbidity, mortality, and costs associated with
the diagnosis are expected to increase exponentially, potentially
overwhelming the global healthcare system. Therefore, the impor-
tance of our results is clear: through careful analyses, we found that
full HFOT at discharge is associated with a consistent reduction in
mortality in patients with recent AHF, regardless of LVEF or the
presence of co-morbidities. In light of the widespread availability
and inexpensive nature of BB and RASi, our results have substantial
© 2017 The Authors
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Figure 4 Survival according to combined treatment at discharge. Panel A shows the hazard ratios (HR) with 95% confidence intervals (CI) of
the unadjusted, adjusted and propensity score (PS)-matched models for 90-day and 1-year mortality according to combinations of beta-blockers
(BB) and renin–angiotensin system inhibitors (RASi: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker) at discharge.
Panel B illustrates the survival of patients treated with RASi on top of BB (continuous line) and PS-matched patients treated with BB alone
(dotted line) (n=2356). Panel C illustrates the survival of patients treated with BB on top of RASi (continuous line) and PS-matched patients
treated with RASi alone (dotted line) (n=3752). Panel D illustrates the survival of all study patients (n=19 980) according to the treatment
regimen: patients with dual treatment (receiving a combination of BB and RASi), partial treatment (receiving either BB or RASi alone) or no
treatment (neither BB nor RASi).
global health implications: administering a combination of at least
oral BB and RASi in all patients with AHF appears justified. As the
care of hospitalized AHF patients is typically not in the hands of
cardiology specialists,31 our data are applicable to a broad range of
medical caregivers globally.
Limitations
The present study has several limitations. Firstly, it was a
non-randomized study. The effects of a drug intervention and
















.. Thus, no firm implications with respect of a causal role between
treatment and outcomes can be driven by the present analysis.
However, propensity score methodology allowed us to balance
groups according to variables that were recorded in the GREAT
registry, reflecting the experience of daily clinical practice in
tertiary centres in Europe and Asia. Despite the large number of
included variables, other factors associated with the administration
of a specific treatment (e.g., frailty, dementia, haemodynamics,
persistent instability at discharge or dosing of chronic medica-
tions) may not have been included in the propensity score and
might result in a bias in the estimates of treatment effectiveness.
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Therefore, a healthy user bias cannot completely be ruled out.
However, missing variables would unlikely interfere with the con-
sistent results of 40% improvement in risk of death consistently
observed in unmatched and matched, unadjusted and adjusted
populations and in many study subgroups, which strongly suggest
that the combination of BB and RASi at discharge is associated with
marked benefits in AHF. We further acknowledge that this study
did not consider temporary discontinuation of HFOTs during
hospitalization nor assess the administered dose of HF therapies
at discharge or changes in HFOT during follow-up. Changes in
the treatment regimen (including withdrawal or introduction)
after hospital discharge might confound the outcomes, especially
long-term mortality. However, previous data showed that HFOTs
prescribed during hospitalization for AHF are often not changed
during the subsequent months.10,32 We also did not examine the
effects of newer HFOTs (such as ivabradine or sacubitril/valsartan)
or devices on survival. A recent study suggests beneficial effects
of maintaining ivabradine at discharge on short-term outcome in
hospitalized HF patients.33 Further prospective, randomized trials
should confirm our present results. As data on black AHF patients
are missing in the present study, future trials should address that
population. The present study also did not address the effect of
HFOT at discharge of AHF on hospital readmission because the
GREAT registry did not report data about subsequent hospitaliza-
tions. Given these limitations, prospective trials are needed.
Conclusions
Our study showed that administration of HFOT at hospital dis-
charge is associated with better survival of AHF patients regardless
of left ventricular systolic function or associated co-morbidities.
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